- Home
- EQ vs GDO Comparison
EQ vs GDO Comparison
Compare EQ & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- GDO
- Stock Information
- Founded
- EQ 2017
- GDO 2009
- Country
- EQ United States
- GDO United States
- Employees
- EQ N/A
- GDO N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- GDO Finance Companies
- Sector
- EQ Health Care
- GDO Finance
- Exchange
- EQ Nasdaq
- GDO Nasdaq
- Market Cap
- EQ 85.1M
- GDO 89.6M
- IPO Year
- EQ 2018
- GDO N/A
- Fundamental
- Price
- EQ $1.39
- GDO $11.60
- Analyst Decision
- EQ Hold
- GDO
- Analyst Count
- EQ 2
- GDO 0
- Target Price
- EQ $1.00
- GDO N/A
- AVG Volume (30 Days)
- EQ 489.3K
- GDO 39.4K
- Earning Date
- EQ 11-11-2025
- GDO 01-01-0001
- Dividend Yield
- EQ N/A
- GDO 9.81%
- EPS Growth
- EQ N/A
- GDO N/A
- EPS
- EQ N/A
- GDO N/A
- Revenue
- EQ $16,553,000.00
- GDO N/A
- Revenue This Year
- EQ N/A
- GDO N/A
- Revenue Next Year
- EQ N/A
- GDO N/A
- P/E Ratio
- EQ N/A
- GDO N/A
- Revenue Growth
- EQ N/A
- GDO N/A
- 52 Week Low
- EQ $0.27
- GDO $11.21
- 52 Week High
- EQ $2.35
- GDO $13.04
- Technical
- Relative Strength Index (RSI)
- EQ 48.48
- GDO 38.01
- Support Level
- EQ $1.31
- GDO $11.50
- Resistance Level
- EQ $1.58
- GDO $11.90
- Average True Range (ATR)
- EQ 0.13
- GDO 0.14
- MACD
- EQ 0.01
- GDO -0.01
- Stochastic Oscillator
- EQ 48.64
- GDO 22.22
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.